OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of:

• Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

• Primary progressive MS, in adults.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Health care professionals are asked to report any suspected adverse reactions at pakistan.drug_safety@roche.com

M-PK-00001196